Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet R Vos

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Cancers|August 26, 2022
Detection and Yield of Colorectal Cancer Surveillance in Adults with <i>PTEN</i> Hamartoma Tumour SyndromeMeggie M C M Drissen, Janet R Vos, Dorien T J van der Biessen-van Beek, et al.
Journal of the National Cancer Institute|July 3, 2024
Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2Lisa Elze, Rachel S van der Post, Janet R Vos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2016
Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation CarriersJanet R Vos, Jan C Oosterwijk, Cora M Aalfs, et al.
European Journal of Human Genetics : EJHG|February 28, 2018
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?Natalia Teixeira, Annemieke van der Hout, Jan C Oosterwijk, et al.
International Journal of Cancer|May 3, 2014
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort studySepideh Saadatmand, Janet R Vos, Maartje J Hooning, et al.
Journal of the National Cancer Institute|May 12, 2019
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionJanet R Vos, Ingrid E Fakkert, Joanne A de Hullu, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variantMaartje A C Schreurs, Muriel A Adank, Bernadette A M Heemskerk-Gerritsen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2014
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the NetherlandsJanet R Vos, Natalia Teixeira, Dorina M van der Kolk, et al.
Cancers|March 13, 2024
Lifestyle Factors and Breast Cancer in Females with PTEN Hamartoma Tumor Syndrome (PHTS)Linda A J Hendricks, Katja C J Verbeek, Janneke H M Schuurs-Hoeijmakers, et al.
European Journal of Medical Genetics|October 21, 2022
Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohortLinda A J Hendricks, Nicoline Hoogerbrugge, Hanka Venselaar, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Cancers|August 26, 2022
Detection and Yield of Colorectal Cancer Surveillance in Adults with <i>PTEN</i> Hamartoma Tumour SyndromeMeggie M C M Drissen, Janet R Vos, Dorien T J van der Biessen-van Beek, et al.
Journal of the National Cancer Institute|July 3, 2024
Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2Lisa Elze, Rachel S van der Post, Janet R Vos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2016
Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation CarriersJanet R Vos, Jan C Oosterwijk, Cora M Aalfs, et al.
European Journal of Human Genetics : EJHG|February 28, 2018
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?Natalia Teixeira, Annemieke van der Hout, Jan C Oosterwijk, et al.
International Journal of Cancer|May 3, 2014
Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort studySepideh Saadatmand, Janet R Vos, Maartje J Hooning, et al.
Journal of the National Cancer Institute|May 12, 2019
Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic PredispositionJanet R Vos, Ingrid E Fakkert, Joanne A de Hullu, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variantMaartje A C Schreurs, Muriel A Adank, Bernadette A M Heemskerk-Gerritsen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 9, 2014
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the NetherlandsJanet R Vos, Natalia Teixeira, Dorina M van der Kolk, et al.
Cancers|March 13, 2024
Lifestyle Factors and Breast Cancer in Females with PTEN Hamartoma Tumor Syndrome (PHTS)Linda A J Hendricks, Katja C J Verbeek, Janneke H M Schuurs-Hoeijmakers, et al.
European Journal of Medical Genetics|October 21, 2022
Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohortLinda A J Hendricks, Nicoline Hoogerbrugge, Hanka Venselaar, et al.
Pageof 4